Grumann Thorsten, Arab Amina, Bode Christoph, Guttenberger Roland, Hehrlein Christoph
Department of Cardiology, University Clinic of Freiburg, Germany.
Strahlenther Onkol. 2006 Jan;182(1):16-21. doi: 10.1007/s00066-006-1374-6.
Catheter-based coronary brachytherapy with beta- and gamma-radiation is an evidence-based method to prevent restenosis after percutaneous transluminal coronary angioplasty (PTCA) and stent implantation, but the outcome may be subject to improvements. Physiological studies suggest that most of the target cells of brachytherapy in coronary arteries after PTCA are hypoxic. A lack of oxygen decreases the effect of low LET (linear energy transfer) irradiation. The authors assumed that reoxygenation of hypoxic human coronary smooth muscle cells (HCSMCs) improves the results of coronary brachytherapy. The expression of hypoxia-inducible factor 1alpha (HIF-1alpha) gene, and the rates of growth and apoptosis of hypoxic and reoxygenated HCSMCs after gamma-irradiation were therefore analyzed.
An in vitro model of megacolonies of HCSMCs was developed. After exposure to chronic hypoxia the HCSMCs were irradiated with graded doses of 2, 4, 8, and 16 Gy using a (60)Co source either under hypoxia (pO(2) < 3 mmHg) or after reoxygenation (pO(2) approximately 150 mmHg). RT-PCR (reverse transcription-polymerase chain reaction) analysis was used to quantify HIF-1alpha gene expression and the growth of HCSMC megacolonies was measured serially. The oxygen enhancement ratio (OER) was calculated from the specific growth delay. Apoptosis of HCSMCs was quantified by counting cells with specific DNA strand breaks using the TUNEL assay.
HIF-1alpha gene expression was markedly suppressed in reoxygenated cells versus hypoxic cells 30 min after gamma-irradiation at all radiation doses (158 +/- 46% vs. 1,675 +/- 1,211%; p < 0.01). Apoptosis was markedly increased in reoxygenated HCSMCs. The OER was 1.8 (95% CI [confidence interval] 1.3-2.4). Therefore, reoxygenated HCSMCs require 44% less radiation dose to achieve the equivalent biological radiation effect compared to hypoxic HCSMCs.
Reoxygenation of coronary smooth muscle cells should be considered an option to increase efficacy of coronary brachytherapy. This could be used to reduce radiation dose and associated late side effects.
基于导管的β射线和γ射线冠状动脉近距离放射治疗是一种预防经皮腔内冠状动脉成形术(PTCA)和支架植入术后再狭窄的循证医学方法,但治疗效果仍有待提高。生理学研究表明,PTCA术后冠状动脉内近距离放射治疗的大多数靶细胞处于缺氧状态。缺氧会降低低线性能量传递(LET)辐射的效果。作者推测,缺氧的人冠状动脉平滑肌细胞(HCSMCs)复氧可改善冠状动脉近距离放射治疗的效果。因此,分析了缺氧诱导因子1α(HIF-1α)基因的表达以及γ射线照射后缺氧和复氧的HCSMCs的生长和凋亡率。
建立了HCSMCs巨集落的体外模型。在暴露于慢性缺氧后,使用(60)Co源在缺氧(pO₂<3 mmHg)或复氧(pO₂约150 mmHg)条件下,用2、4、8和16 Gy的分级剂量对HCSMCs进行照射。采用逆转录聚合酶链反应(RT-PCR)分析定量HIF-1α基因表达,并连续测量HCSMCs巨集落的生长情况。根据特定的生长延迟计算氧增强比(OER)。使用TUNEL法通过计数具有特定DNA链断裂的细胞来定量HCSMCs的凋亡。
在所有辐射剂量下,γ射线照射30分钟后,复氧细胞中的HIF-1α基因表达与缺氧细胞相比明显受到抑制(158±46%对1675±1211%;p<0.01)。复氧的HCSMCs凋亡明显增加。OER为1.8(95%置信区间[CI]1.3 - 2.4)。因此,与缺氧的HCSMCs相比,复氧的HCSMCs达到等效生物辐射效应所需的辐射剂量减少44%。
冠状动脉平滑肌细胞复氧应被视为提高冠状动脉近距离放射治疗疗效一种选择。这可用于减少辐射剂量及相关的晚期副作用。